Invasight and Eurofins Discovery collaborate

Invasight and Eurofins Discovery have announced a collaboration, which will see the two companies combining their respective specific qualities in drug research to develop a preclinical candidate against a protein that causes cancer cell invasion.

The spin-off from the University of Zurich, which is based at Balgrist Campus in Zurich and at BaseLink’s main campus in Allschwil in the canton of Basel-Country, has developed the ACINDA (anti-cancer cell invasion drug discovery accelerator) platform. Eurofins Discovery described it as a “breakthrough technology” in a press release. The Californian company provides products and services for drug development. It sees itself as an outsourcing partner for all drug research programs.

According to the press release, the DiscoveryOne team’s successful track record and experience developing drug candidates together with Invasight’s cancer cell invasion models “are expected to result in high-quality molecules moving rapidly to IND-enabling studies to accelerate therapeutics in the fight against cancer.” mm